Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan

被引:14
|
作者
Hsu, Ching-Sheng
Liu, Chun-Jen
Lai, Ming-Yang
Chen, Pei-Jer
Kao, Jia-Horng
Chen, Ding-Shinn
机构
[1] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei 100, Taiwan
[2] Buddhist Tzu Chi Gen Hosp, Dept Hepatogastroenterol, Dept Internal Med, Taipei Branch, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Coll Med, Dept Med Res, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Coll Med, Hepatitis Res Ctr, Taipei 10764, Taiwan
[6] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
关键词
hepatitis C virus; viral kinetics; pegylated interferon; interferon; ribavirin;
D O I
10.1159/000105444
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objectives: Early hepatitis C viral ( HCV) kinetics following pegylated interferon-alpha (PEG-IFN) and ribavirin help to assess treatment in the Western world. Whether this functions in Taiwanese patients remains unknown. Studying the early HCV kinetics in Taiwanese patients may clarify this issue. Methods: Six chronic hepatitis C patients were enrolled. A PEG-IFN-alpha dose was administered at week 1, then it was administered weekly with daily ribavirin for 24 weeks. Serum HCV RNA levels were determined frequently during the trial and qualitatively at week 49. Kinetic parameters epsilon ( effectiveness at inhibiting viral production) and delta ( loss rate of infected cells) were estimated from viral loads and alanine aminotransferase ( ALT) kinetics, respectively. Results: All serum HCV RNA levels became undetectable at week 12. The epsilon ranged from 0.4128 to 0.9904 and delta from 0.0019 to 0.1245. The log values of viral load differences between day 7 and 14 ranged from 0.15 to 1.21. Only 1 patient had an abnormal ALT level at week 49. Conclusions: Viral kinetic parameters in Taiwanese patients were similar to those in Western studies. However, the early viral decline pattern and viral negativity rate in Taiwanese patients might be different from Caucasian patients. Further large-scale studies to clarify this issue are ongoing. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 50 条
  • [41] Chronic hepatitis C: Treatment of pegylated interferon/ribavirin nonresponders
    Shiffman M.L.
    [J]. Current Hepatitis Reports, 2006, 5 (3) : 114 - 120
  • [42] Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.
    Cornberg M.
    Wedemeyer H.
    Manns M.P.
    [J]. Current Gastroenterology Reports, 2002, 4 (1) : 23 - 30
  • [43] Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C - A cochrane systematic review
    Simin, M
    Brok, F
    Stimac, D
    Gluud, C
    Gluud, LL
    [J]. HEPATOLOGY, 2005, 42 (04) : 666A - 666A
  • [44] Fatal Neutropenic Enterocolitis during Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection
    Kim, Ji Hun
    Jang, Jeong Won
    You, Chan Ran
    You, Si Young
    Jung, Mun Kyung
    Jung, Jin Hwan
    [J]. GUT AND LIVER, 2009, 3 (03) : 218 - 221
  • [45] Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during treatment with pegylated interferon alfa-2a plus ribavirin
    Pugnale, Paolo
    Herrmann, Eva
    Neumann, Avidan U.
    Pawlotsky, Jean-Michel
    Schalm, Solko W.
    Ferrari, Carlo
    Homburger, Yonit
    Zeuzem, Stefan
    Negro, Francesco
    [J]. HEPATOLOGY, 2007, 46 (04) : 349A - 349A
  • [46] Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation
    Annicchiarico, B. E.
    Siciliano, M.
    Avolio, A. W.
    Caracciolo, G.
    Gasbarrini, A.
    Agnes, S.
    Castagneto, M.
    [J]. TRANSPLANTATION PROCEEDINGS, 2008, 40 (06) : 1918 - 1920
  • [47] Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon
    Herrmann, E
    Lee, JH
    Marinos, G
    Modi, M
    Zeuzem, S
    [J]. HEPATOLOGY, 2003, 37 (06) : 1351 - 1358
  • [48] Staphylococcus aureus bacteremia in patients receiving pegylated interferon-alpha and ribavirin for chronic hepatitis C virus infection
    Webster, D.
    Ahmed, R.
    Tandon, P.
    Chui, L.
    McDonald, R. R.
    Obarianyk, A.
    Antonishyn, N.
    Doucette, K.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2007, 14 (08) : 564 - 569
  • [49] IMPROVEMENT OF BIOMARKERS OF LIVER INSUFFICIENCY AFTER TREATMENT OF HEPATITIS C VIRUS INFECTION WITH PEGYLATED INTERFERON/RIBAVIRIN PLUS RITUXIMAB
    Geri, Guillaume
    Terrier, Benjamin
    Imbert-Bismut, Francoise
    Saadoun, David
    Sene, Damien
    Poynard, Thierry
    Cacoub, Patrice
    [J]. HEPATOLOGY, 2010, 52 (04) : 815A - 815A
  • [50] Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment
    Elefsiniotis, Ioannis S.
    Petrocheilou, Aikaterini
    Scarmeas, Nikolaos
    Ketikoglou, Ioannis
    Pantazis, Konstantinos D.
    Toutouza, Marina
    Tsianos, Epameinondas V.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2006, 37 (04) : 329 - 331